Titre : Orphénadrine

Orphénadrine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Databases, Factual
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Orphénadrine : Questions médicales les plus fréquentes", "headline": "Orphénadrine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Orphénadrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-18", "dateModified": "2025-03-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Orphénadrine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés benzhydryliques", "url": "https://questionsmedicales.fr/mesh/D001559", "about": { "@type": "MedicalCondition", "name": "Composés benzhydryliques", "code": { "@type": "MedicalCode", "code": "D001559", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.455.426.559.389.115" } } }, "about": { "@type": "MedicalCondition", "name": "Orphénadrine", "alternateName": "Orphenadrine", "code": { "@type": "MedicalCode", "code": "D009966", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "L S Sorokina", "url": "https://questionsmedicales.fr/author/L%20S%20Sorokina", "affiliation": { "@type": "Organization", "name": "Petrovsky Russian Research Center of Surgery, Moscow, Russia." } }, { "@type": "Person", "name": "D V Ryabova", "url": "https://questionsmedicales.fr/author/D%20V%20Ryabova", "affiliation": { "@type": "Organization", "name": "Petrovsky Russian Research Center of Surgery, Moscow, Russia." } }, { "@type": "Person", "name": "A A Eremenko", "url": "https://questionsmedicales.fr/author/A%20A%20Eremenko", "affiliation": { "@type": "Organization", "name": "Petrovsky Russian Research Center of Surgery, Moscow, Russia." } }, { "@type": "Person", "name": "Shereen A Boltia", "url": "https://questionsmedicales.fr/author/Shereen%20A%20Boltia", "affiliation": { "@type": "Organization", "name": "Cairo University, Faculty of Pharmacy, Analytical Chemistry Department, Kasr El-Aini St, Cairo 11562, Egypt." } }, { "@type": "Person", "name": "Aya T Soudi", "url": "https://questionsmedicales.fr/author/Aya%20T%20Soudi", "affiliation": { "@type": "Organization", "name": "Cairo University, Faculty of Pharmacy, Analytical Chemistry Department, Kasr El-Aini St, Cairo 11562, Egypt." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prognostic factors and survival prediction of resected non-small cell lung cancer with ipsilateral pulmonary metastases: a study based on the Surveillance, Epidemiology, and End Results (SEER) database.", "datePublished": "2023-10-30", "url": "https://questionsmedicales.fr/article/37899470", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12890-023-02722-y" } }, { "@type": "ScholarlyArticle", "name": "Association between lactate/albumin ratio and 28-day all-cause mortality in ischemic stroke patients without reperfusion therapy: a retrospective analysis of the MIMIC-IV database.", "datePublished": "2023-10-12", "url": "https://questionsmedicales.fr/article/37900597", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fneur.2023.1271391" } }, { "@type": "ScholarlyArticle", "name": "The association of handgrip strength with all-cause and cardiovascular mortality: results from the National Health and Nutrition Examination Survey database prospective cohort study with propensity score matching.", "datePublished": "2023-09-15", "url": "https://questionsmedicales.fr/article/37781126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fnut.2023.1183973" } }, { "@type": "ScholarlyArticle", "name": "Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases.", "datePublished": "2023-08-04", "url": "https://questionsmedicales.fr/article/37540472", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s41669-023-00424-z" } }, { "@type": "ScholarlyArticle", "name": "Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37071555", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/45263" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés chimiques organiques", "item": "https://questionsmedicales.fr/mesh/D009930" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures", "item": "https://questionsmedicales.fr/mesh/D006838" }, { "@type": "ListItem", "position": 4, "name": "Hydrocarbures cycliques", "item": "https://questionsmedicales.fr/mesh/D006844" }, { "@type": "ListItem", "position": 5, "name": "Hydrocarbures aromatiques", "item": "https://questionsmedicales.fr/mesh/D006841" }, { "@type": "ListItem", "position": 6, "name": "Dérivés du benzène", "item": "https://questionsmedicales.fr/mesh/D001555" }, { "@type": "ListItem", "position": 7, "name": "Composés benzhydryliques", "item": "https://questionsmedicales.fr/mesh/D001559" }, { "@type": "ListItem", "position": 8, "name": "Orphénadrine", "item": "https://questionsmedicales.fr/mesh/D009966" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Orphénadrine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Orphénadrine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Orphénadrine", "description": "Comment diagnostiquer une douleur musculaire nécessitant l'orphénadrine ?\nQuels tests sont utiles avant de prescrire l'orphénadrine ?\nL'orphénadrine est-elle indiquée pour tous les types de douleurs ?\nQuels signes cliniques justifient l'utilisation de l'orphénadrine ?\nL'orphénadrine est-elle utilisée en cas de fibromyalgie ?", "url": "https://questionsmedicales.fr/mesh/D009966?mesh_terms=Databases,+Factual&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Orphénadrine", "description": "Quels sont les effets secondaires courants de l'orphénadrine ?\nL'orphénadrine peut-elle provoquer des réactions allergiques ?\nQuels symptômes indiquent une surdose d'orphénadrine ?\nL'orphénadrine peut-elle causer des troubles de la vision ?\nQuels symptômes nécessitent l'arrêt immédiat de l'orphénadrine ?", "url": "https://questionsmedicales.fr/mesh/D009966?mesh_terms=Databases,+Factual&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Orphénadrine", "description": "Comment prévenir les douleurs nécessitant l'orphénadrine ?\nL'alimentation joue-t-elle un rôle dans la prévention des douleurs musculaires ?\nLe stress peut-il aggraver les douleurs musculaires ?\nDes étirements réguliers peuvent-ils prévenir les douleurs ?\nLe repos est-il important pour prévenir les douleurs musculaires ?", "url": "https://questionsmedicales.fr/mesh/D009966?mesh_terms=Databases,+Factual&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Orphénadrine", "description": "Comment l'orphénadrine est-elle administrée ?\nQuelle est la posologie standard de l'orphénadrine ?\nL'orphénadrine peut-elle être combinée avec d'autres médicaments ?\nQuels sont les avantages de l'orphénadrine par rapport à d'autres traitements ?\nL'orphénadrine est-elle efficace contre les douleurs chroniques ?", "url": "https://questionsmedicales.fr/mesh/D009966?mesh_terms=Databases,+Factual&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Orphénadrine", "description": "Quelles complications peuvent survenir avec l'orphénadrine ?\nL'orphénadrine peut-elle entraîner une dépendance ?\nQuels signes indiquent une complication grave de l'orphénadrine ?\nComment gérer les complications liées à l'orphénadrine ?\nL'orphénadrine peut-elle affecter la fonction hépatique ?", "url": "https://questionsmedicales.fr/mesh/D009966?mesh_terms=Databases,+Factual&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Orphénadrine", "description": "Quels facteurs augmentent le risque d'effets secondaires de l'orphénadrine ?\nLes personnes âgées sont-elles plus sensibles à l'orphénadrine ?\nL'usage d'alcool influence-t-il l'efficacité de l'orphénadrine ?\nLes antécédents médicaux influencent-ils l'utilisation de l'orphénadrine ?\nLes femmes enceintes peuvent-elles prendre de l'orphénadrine ?", "url": "https://questionsmedicales.fr/mesh/D009966?mesh_terms=Databases,+Factual&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une douleur musculaire nécessitant l'orphénadrine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'historique des symptômes." } }, { "@type": "Question", "name": "Quels tests sont utiles avant de prescrire l'orphénadrine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie et des analyses sanguines peuvent être réalisés pour évaluer l'état musculaire." } }, { "@type": "Question", "name": "L'orphénadrine est-elle indiquée pour tous les types de douleurs ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est principalement indiquée pour les douleurs musculaires et les spasmes." } }, { "@type": "Question", "name": "Quels signes cliniques justifient l'utilisation de l'orphénadrine ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des douleurs aiguës, des spasmes et une raideur musculaire." } }, { "@type": "Question", "name": "L'orphénadrine est-elle utilisée en cas de fibromyalgie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être utilisée pour soulager certains symptômes de la fibromyalgie." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de l'orphénadrine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent la sécheresse buccale, la somnolence et des vertiges." } }, { "@type": "Question", "name": "L'orphénadrine peut-elle provoquer des réactions allergiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réactions allergiques comme des éruptions cutanées peuvent survenir." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surdose d'orphénadrine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent confusion, hallucinations et tachycardie." } }, { "@type": "Question", "name": "L'orphénadrine peut-elle causer des troubles de la vision ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner une vision floue ou des troubles visuels temporaires." } }, { "@type": "Question", "name": "Quels symptômes nécessitent l'arrêt immédiat de l'orphénadrine ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des palpitations, des éruptions cutanées ou des difficultés respiratoires." } }, { "@type": "Question", "name": "Comment prévenir les douleurs nécessitant l'orphénadrine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices réguliers, une bonne posture et des pauses fréquentes peuvent aider." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention des douleurs musculaires ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut contribuer à la santé musculaire." } }, { "@type": "Question", "name": "Le stress peut-il aggraver les douleurs musculaires ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les tensions musculaires et les douleurs." } }, { "@type": "Question", "name": "Des étirements réguliers peuvent-ils prévenir les douleurs ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les étirements réguliers aident à maintenir la flexibilité et à prévenir les douleurs." } }, { "@type": "Question", "name": "Le repos est-il important pour prévenir les douleurs musculaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un repos adéquat est essentiel pour la récupération musculaire." } }, { "@type": "Question", "name": "Comment l'orphénadrine est-elle administrée ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle est généralement administrée par voie orale sous forme de comprimés." } }, { "@type": "Question", "name": "Quelle est la posologie standard de l'orphénadrine ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie standard est de 100 mg deux fois par jour, selon les besoins." } }, { "@type": "Question", "name": "L'orphénadrine peut-elle être combinée avec d'autres médicaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, mais il est important de consulter un médecin pour éviter les interactions." } }, { "@type": "Question", "name": "Quels sont les avantages de l'orphénadrine par rapport à d'autres traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elle offre un soulagement rapide des spasmes musculaires et des douleurs." } }, { "@type": "Question", "name": "L'orphénadrine est-elle efficace contre les douleurs chroniques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être efficace pour certaines douleurs chroniques, mais pas pour toutes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'orphénadrine ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des troubles cardiaques ou des problèmes neurologiques peuvent survenir." } }, { "@type": "Question", "name": "L'orphénadrine peut-elle entraîner une dépendance ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elle a un faible potentiel de dépendance, mais une utilisation prolongée doit être surveillée." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave de l'orphénadrine ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques, des évanouissements ou des convulsions." } }, { "@type": "Question", "name": "Comment gérer les complications liées à l'orphénadrine ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Il est crucial de consulter un médecin pour ajuster le traitement ou changer de médicament." } }, { "@type": "Question", "name": "L'orphénadrine peut-elle affecter la fonction hépatique ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests de la fonction hépatique peuvent être nécessaires en cas d'utilisation prolongée." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'effets secondaires de l'orphénadrine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, les maladies préexistantes et l'utilisation d'autres médicaments augmentent le risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus sensibles à l'orphénadrine ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent être plus sensibles aux effets secondaires de l'orphénadrine." } }, { "@type": "Question", "name": "L'usage d'alcool influence-t-il l'efficacité de l'orphénadrine ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'alcool peut augmenter les effets sédatifs de l'orphénadrine." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils l'utilisation de l'orphénadrine ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies cardiaques ou neurologiques peuvent limiter son utilisation." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles prendre de l'orphénadrine ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'orphénadrine doit être utilisée avec prudence chez les femmes enceintes, après avis médical." } } ] } ] }

Sources (10000 au total)

Prognostic factors and survival prediction of resected non-small cell lung cancer with ipsilateral pulmonary metastases: a study based on the Surveillance, Epidemiology, and End Results (SEER) database.

Prognostic factors and survival outcomes of non-small cell lung cancer (NSCLC) with Ipsilateral pulmonary metastasis (IPM) are not well-defined. Thus, this study intended to identify the prognostic fa... One thousand, seven hundred thirty-two patients with IPM identified between 2000 to 2019 were from the Surveillance, Epidemiology, and End Results (SEER) database. Independent prognostic factors were ... Patients were randomly divided into training (n = 1213) and validation (n = 519) cohorts. In the training cohort, the multivariable analysis demonstrated that age, sex, primary tumor size, N status, n... We constructed and internally validated a nomogram to predict 1-year, 3-year, and 5-year OS for NSCLC patients with IPM according to independent prognostic factors. This nomogram demonstrated good cal...

Association between lactate/albumin ratio and 28-day all-cause mortality in ischemic stroke patients without reperfusion therapy: a retrospective analysis of the MIMIC-IV database.

The lactate/albumin ratio (LAR) has been used as a novel prognostic indicator for aneurysmal subarachnoid hemorrhage, traumatic brain injury, sepsis, heart failure, and acute respiratory failure. Howe... This retrospective cohort study used data from the Medical Information Mart for Intensive Care (MIMIC-IV) (v2.0) database. It included 568 IS adult patients admitted to the intensive care unit (ICU). ... Among the 568 patients with IS, 370 survived (survival group) and 198 died (non-survival group) within 28 days of admission (mortality rate: 34.9%). A multivariate COX regression analysis indicated th... LAR can serve as an independent predictor of all-cause mortality within 28 days after admission for patients with IS....

The association of handgrip strength with all-cause and cardiovascular mortality: results from the National Health and Nutrition Examination Survey database prospective cohort study with propensity score matching.

To investigate the association between handgrip strength (HGS) with all-cause and cardiovascular disease (CVD) mortality in US adults.... We analyzed data from the National Health and Nutrition Examination Survey (NHANES) prospective cohort study (2011-2014) with 10,470 participants. The cox regression analysis, Kaplan-Meier survival cu... The low HGSs (men <37.4 kg, women <24 kg), was found to be associated with higher all-cause and CVD mortality in a reverse J-shaped curve (... Adults with low HGS exhibited a significantly increased risk of both all-cause and CVD mortality, regardless of gender. Additionally, low HGS served as an independent risk factor and predictor for bot...

Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases.

Crohn's-related rectovaginal fistulas (RVF) greatly impact quality of life and are notoriously difficult to treat. The aim of this study was to assess the burden of recurrent episodes of care for RVF ... A retrospective observational cohort study of administrative US claims databases was conducted. Eligible patients were female adults, with a diagnosis code for Crohn's disease with or without a diagno... Mean ages in the RVF cohort (n = 963) and RVF-free cohort (n = 56,564) were 47.2 and 50.8 years, with a mean follow-up period of 58.7 and 49.8 months, respectively. For the RVF cohort, the probability... This real-world study highlights the significant impact of RVF in patients with Crohn's disease with regard to repeat interventions and associated HCRU and direct healthcare costs, suggesting novel th...

Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database.

The World Health Organization recently described sudden sensorineural hearing loss (SSNHL) as a possible adverse effect of COVID-19 vaccines. Recent discordant pharmacoepidemiologic studies invite rob... This nationwide study aimed to assess the relationship between SSNHL and exposure to mRNA COVID-19 vaccines and estimate the reporting rate (Rr) of SSNHL after mRNA vaccination per 1 million doses (pr... We performed a retrospective review of all suspected cases of SSNHL after mRNA COVID-19 vaccination spontaneously reported in France between January 2021 and February 2022 based on a comprehensive med... From 400 extracted cases for tozinameran and elasomeran, 345 (86.3%) spontaneous reports were selected. After reviewing complementary data, 49.6% (171/345) of documented cases of SSNHL were identified... SSNHL after COVID-19 mRNA vaccines are very rare adverse events that do not call into question the benefits of mRNA vaccines but deserve to be known given the potentially disabling impact of sudden de...

Outcome and complication comparison for intramedullary nail versus open reduction internal fixation in humeral diaphyseal fractures for 2800 matched patient pairs utilizing the Nationwide Readmissions Database.

Open reduction internal fixation (ORIF) and intramedullary nail fixation (IMN) are the predominant repair methods for operative treatment of humeral diaphyseal fractures; however, the optimal method i... Data collected from 2015 to 2017 from the Nationwide Readmissions Database were evaluated to compare the prevalence of six adverse outcomes: radial nerve palsy, infections, nonunion, malunion, delayed... Following an ORIF procedure, there was a greater odds of undergoing revision surgery (p = 0.03) or developing at least one of the complications of interest (p = 0.03). In the age-stratified analysis, ... IMN and ORIF for humeral diaphyseal fractures are comparable in regard to complications revision rates in patients under the age of 60. Meanwhile, patients 60 + years show a statistically significant ...

Influence of time from admission to norepinephrine administration and volume of fluids received on outcomes of patients meeting sepsis-3 criteria: a retrospective study using the MIMIC-IV database.

Vasopressors are a cornerstone in the management of sepsis, marked by distributive shock often unresponsive to fluid resuscitation. Prior research and clinician surveys have suggested that earlier usa... A retrospective cohort was constructed using patient data contained within the Medical Information Mart for Intensive Care-IV database. Analytic cohort included a total of 2079 patients meeting sepsis... Time to NE use was defined as either early, using <6 hours from time of ICU admission or late using >6 hours to ≤24 hours. Patients who received early NE had significantly lower adjusted odds of morta... Among patients admitted to the ICU for sepsis, early use of NE was associated with significantly lower odds of mortality but higher odds of mechanical ventilation, and no significant difference in len... Level IV-therapeutic care/management....

Red blood cell distribution width/platelet ratio on admission as a predictor for in-hospital mortality in patients with acute myocardial infarction: a retrospective analysis from MIMIC-IV Database.

Red blood cell distribution width (RDW) to platelet ratio (RPR) is a novel inflammatory indicator. It integrates the risk prediction of RDW and platelet, which is associated with adverse outcomes. How... Data on patients with AMI were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients were divided into two groups according to the optimal RPR cut-off value. ... A total of 1266 patients were enrolled, of which 83 (6.8%) died within 180 days during the hospitalization. Compared with the survivor group, the non-survivor group had higher RPR on admission (0.11 ±... Higher RPR was associated with higher in-hospital 180-day mortality in patients with AMI....